Form 4: Inhibikase Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
David McIntyre, CFO of Inhibikase Therapeutics, Inc., reports the acquisition of stock options.
Summary
- David McIntyre, the Chief Financial Officer of Inhibikase Therapeutics, Inc. (IKT), filed a Form 4 with the SEC.
- The filing reports the acquisition of 1,775,539 stock options on April 14, 2025, at an exercise price of $2.
- These options vest over time, with 25% vesting on April 14, 2026, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continued employment.
- Following the transaction, McIntyre directly owns 1,775,539 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock option grant, which is neither particularly positive nor negative. It's a routine disclosure.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- The acquisition of stock options by the CFO aligns his interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 04/14/2025 | Date of earliest transaction and acquisition of stock options. |
| 04/14/2026 | 25% of the acquired stock options vest. |
| 04/14/2035 | Expiration date of the stock options. |
| 04/16/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Inhibikase Therapeutics, IKT, David McIntyre, CFO, Stock Options, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.